Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
Top Cited Papers
- 10 May 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (14) , 2323-2330
- https://doi.org/10.1200/jco.2009.25.0068
Abstract
Purpose Mutations in the RET proto-oncogene and vascular endothelial growth factor receptor (VEGFR) activity are critical in the pathogenesis of medullary thyroid cancer (MTC). Sorafenib, a multiki...This publication has 28 references indexed in Scilit:
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid CancerJournal of Clinical Oncology, 2009
- Phase II Trial of Sorafenib in Metastatic Thyroid CancerJournal of Clinical Oncology, 2009
- Phase II Trial of Sorafenib in Advanced Thyroid CancerJournal of Clinical Oncology, 2008
- Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnibMolecular Cancer Therapeutics, 2008
- Thyroid carcinoma: molecular pathways and therapeutic targetsLaboratory Investigation, 2008
- Sometimes Size Doesn't Matter: Reevaluating RECIST and Tumor Response Rate EndpointsJNCI Journal of the National Cancer Institute, 2006
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Prognostic value of codon 918 (ATG?ACG)RET proto-oncogene mutations in sporadic medullary thyroid carcinomaInternational Journal of Cancer, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989